EUROPEAN COMMISSION
JOINT RESEARCH CENTRE

Directorate F – Health and Food
Disease Prevention

Annual Declaration of Interests[1] (DoI) form
(v2, 01 July 2026)

European Commission initiative on Lung Cancer (EC-LuC)

Please answer each of the questions below.
If the answer to any of the questions is "Yes"[2], please complete the corresponding fields, describing the circumstances, as appropriate.

If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the EC-LuC activities.
If you do not disclose relevant activities of interest for the EC-LuC, your role may be revised.

[1] According to EC's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 10, each member of an expert group has to complete a DoI form
https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en

[2] Answering "Yes" to the questions on this form does not automatically limit your participation in the EC-LuC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (*i.e.* any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

Name and Surname:	Prof. Dr. Torsten Gerriet Blum

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
1. Do you have current investments[3] in a legal entity[4] with an interest related to lung cancer which either: **• has a value of more than 10.000 EUR, or** **• entitles you to a voting right of 5% or more?**	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of entity; • Place; • Type of entity: public, private.	[Please describe your role.]

[3] **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (*e.g.*, proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).

[4] **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
2. Within the past 5 years, were you employed (remunerated or non-remunerated post) or have you had any other professional relationship with a legal entity or any other body, with an interest related to lung cancer? **A. Employment**	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of the entity; • Place; • Type of entity: public, private; • Received amounts for remunerated activities.	[Please describe your role.]
B. Consultancy, including advisory activities	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of the entity; • Place; • Type of the entity: public, private; • Received amounts for remunerated activities.	[Please describe your role.]

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
C. Non-remunerated post	Yes ☒ No ☐	10/2021 – 09/2024	If 'ye's, please specify: • Name of the entity; • Place; • Type of the entity: public, private;	10/2021-09/2024 Positions of Head of Thoracic Oncology Assembly, Science Council Member and Executive Council Member within European Respiratory Society (Switzerland, public)
D. Legal representation[5]	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of the entity; • Place; • Type of the entity: public, private;	[Please describe your role.]

[5] **Legal representation** refers to the representation of natural or legal persons through other persons in accordance with national law. For example, the president of a company is the legal representative of that company.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
3. Regarding research related to lung cancer within the past 5 years: **A. Have you been an investigator in research studies on lung cancer?**	Yes ☒ No ☐	10/2021 – ongoing	If 'yes', please specify if you have been a principal investigator. Please mention the title of each study.	EU IMI OPTIMA (Role: Clinical Lead Lung Cancer, multiple real-world-evidence based research studies, duration: 5 years, start October 1,2021) EU IHI IDERHA (Role: Clinical Lead Lung Cancer, multiple real-world-evidence based research studies, duration 5 years, start April 1, 2023) EU4Health SOLACE (Role: Scientific Coordination Team Member, multiple implementation research studies, duration 3 years, start April 1, 2023) EU4Health LAPIN (Role: Investigator, modelling studies, duration 18 months, start November 1, 2025)

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
B. If yes, for the aforementioned research studies, did you receive support[6]?	Yes ☒ No ☐	10/2021 – ongoing	If 'yes', please specify: • Type of received support: grants, funds; • Entity which offered the support: name, place, type (public, private); • Received amounts (for public grants please also specify the annual budget of your home institution).	EU IMI OPTIMA: no funds received (Helios not eligible for funding) EU IHI IDERHA: EU IHI grant, 763,152.50 € for Medical School Berlin EU4Health SOLACE: EU4Health grant, 618,672 € for Medical School Berlin EU4Health LAPIN: EU4Health grant, 29,660 € for Medical School Berlin

[6] **Support** refers to research support (i.e. grants, collaborations, sponsorships) as well as to non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
4. Do you have membership in national or international organisations[7], including committees, working groups, collaborative platforms, managing bodies or scientific advisory bodies or any decision making bodies with an interest in lung cancer?	Yes ☒ No ☐	2008 – ongoing	If 'yes', please specify: • Name, • Place; • Type: public, private, etc. (list all if more than one).	See also 2C: Long-standing member of European Respiratory Society (Switzerland, public) since 2008, last positions: 10/2021-09/2024 Positions of Head of Thoracic Oncology Assembly, Science Council Member and Executive Council Member Long-standing member of German Respiratory Society (no positions)
5. Do you have intellectual property rights (IPR)[8] related to lung cancer?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please specify the title of the IPR.	[Please describe the IPR.]

[7] **Organisation** refers to a governmental, international or non-profit organisation.

[8] **Intellectual property rights** refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
6. Within the past 5 years: **A. Have you provided any expert opinion or testimony in the field of lung cancer, for a legal entity or other body as part of a regulatory, legislative or judicial process?**	Yes ☒ No ☐	2023 – 2026	Please mention the activity.	Provisions of expert opinion relating to the implementation of Lung Cancer Screening in Germany to German regulatory bodies: -German Federal Ministry of Environment, Nature Conservation, and Nuclear Safety -Federal Joint Committee (G-BA) as representative of the German Respiratory Society
B. Have you held an office or other position, paid or unpaid, where you represented interests or defended an opinion in the field of lung cancer?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please mention the activity.	[Please describe the activity.]
7. Do any of your immediate family members[9] have direct interests related to lung cancer that could undermine your independence?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please mention the interest.	[Please describe the interest.]

[9] **Immediate family members** refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
8. Within the past 5 years, did you take part in other activities with interests related to lung cancer?	Yes ☒ No ☐	2021 – 2025	Please specify the title of the activity.	Online and on-site talks paid by industry (AstraZeneca, J&J, Lilly, MSD, Pfizer, Roche), payments only to employer (according to Helios compliance policy), no personal payments or remunerations received

Notes:

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published[10] before you send the DoI form to the Joint Research Centre (JRC), EC.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending an e-mail as soon as possible at: JRC-CANCER-POLICY-SUPPORT@ec.europa.eu.

☒ **I hereby declare the information disclosed in this form is true and complete to the best of my knowledge.**

☒ **I agree my DoI form to be publicly available on the EC's web-hub on cancer screening and care, during the EC-LuC membership[11].**

☒ **I am informed that my personal data are stored, processed and published by the EC in accordance with Regulation (EU) 2018/1725[12].**

Name and Surname: Prof. Dr. Torsten Gerriet Blum **Date: July 23, 2027**

Signature:

Place: Berlin, Germany

[10] Personal data processing including the DoI
https://ec.europa.eu/dpo-register/detail/DPR-EC-00656
[11] Note: Technical measures are in place to ensure that search engines do not index the content from the DoI form.
[12] Protection of individuals with regard to the processing of personal data
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725